Latham & Watkins Represents Zentalis Pharmaceuticals in US$250 Million Underwritten Offering of Common Stock

Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, has announced the pricing of an underwritten offering of 11,032,656 shares of its common stock at an offering price of US$22.66 per share, for total gross proceeds of approximately US$250.0 million, before deducting underwriting discounts and commissions and offering expenses payable by the Company. All of the common stock is being offered by the Company. The offering is expected to close on June 20, 2023, subject to customary closing conditions.

Latham & Watkins LLP represents Zentalis in the offering with a New York corporate team led by partners Nathan Ajiashvili and Salvatore Vanchieri, with associates Matt DeSilva, Darby Dietrich, and Rachel Moore.